Genmab | GEN - Current Liabilities


Genmab reported DKK1.43B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Almirall EUR 350.64M 52.12M Dec/2025
Amarin USD 179.64M 14.82M Mar/2026
Amgen USD 24.96B 534M Mar/2026
argenx SE USD 1.32B 278.28M Dec/2025
AstraZeneca USD 32.57B 1.95B Mar/2026
Bayer EUR 33.46B 875M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Demant DKK 7.42B 1.63B Dec/2025
Exelixis USD 370.98M 34.67M Mar/2026
Fresenius Medical Care EUR 6.73B 484.42M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
GN Store Nord DKK 4.81B 2.5B Mar/2026
GRIFOLS EUR 2.12B 105M Mar/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Insmed USD 361.01M 107.87M Mar/2026
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 9.04B 405M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
UCB EUR 4.4B 470M Dec/2025